Skip to main navigation
logo
  • About Us
    • Board of Directors
    • Management
  • Our Science
    • Oncolytic Immunotherapy
    • The Immulytic Platform
  • Pipeline
  • Investors and Media
    • Overview
    • Events and Presentations
    • Press Releases
    • Corporate Governance
    • Financials & Filings
    • Stock Information
    • Publications
    • Email Alerts
    • Investor Contact
  • Careers
  • Contact
Select Page

Publications

Publications

Journal for ImmunoTherapy of Cancer: Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1
Aug 10, 2019
Oncolytic immunotherapy: An emerging new modality for the treatment of cancer
May 01, 2016
Infectious Enthusiasm
Feb 29, 2016
Interview with Robert Coffin, inventor of T-VEC: the first oncolytic immunotherapy approved for the treatment of cancer.
Feb 01, 2016
Print Page
RSS Feeds RSS Feeds
Email Alerts Email Alerts
Contact IR Contact IR
Search Search

© 2018 Replimune Group Inc
18 Commerce Way, Woburn, MA 01801 Privacy | Terms